BioSpace News Archive

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com ), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that it has expanded its engagement with MCRA, the leading U.S. regulatory group for medical devices and biologics, with over 600 client engagements, globally, to continue to advance the Company’s FDA program. MCRA will participate in develo

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D., Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10:00 a.m. ET. A live webcast of the presentation will be available on the investor section of the Abeona Therapeutics website at www.abeonatherapeutics.com . The webcast replay will be av

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares are being sold by Arena. The gross proceeds from the offering are expected to be $275.0 million , before deducting the underwritin

- Exploratory endpoint analyses demonstrated Allocetra’s potential therapeutic effect in resolving cytokine storms in patients with heterogenous pathologies Nes Ziona, Israel, May 28, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that new analyses from its recently completed Phase Ib clinical trial of Allocetra TM in patients with sepsis will be presented as part of an oral presentation at the International Soci

Venture.co Brokerage Services, LLC (“VENTURE.co”) today announces a private capital investment opportunity into HemaFlo Therapeutics, Inc. (“HemaFlo”). VENTURE.co, the Managing Broker-Dealer, will facilitate the $7.5 million ca

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Jefferies 2020 Virtual Healthcare Conference taking place June 2-4, 2020. The Company’s presentation will be on Thursday, June 4, 2020 at 2:30 p.m. ET. Interested parties can access a live webcast of the presentation via a link

After learning that government agencies and hospitals worldwide could not expeditiously obtain the proper FDA-approved personal protection equipment (PPE) and medical supplies that they needed to fight COVID-19, that various state agencies and hospitals were bidding against one another due to a severe supply shortages, and reports of front line medical workers using garbage bags for protection because they did not have the proper PPE,

– Maintained production operations during COVID-19 pandemic crisis, providing our customers essential products while ensuring the health and safety of our employees – – R&D activities focused on the development of innovative delivery systems – – First quarter 2020 sales increased 34% vs. first quarter 2019 – – Net profit of $1,126,000 for Q1 2020 vs. net loss of $637,000 for Q1 2019 –

How Mice That Model Immune Disease’s Cytokine Storms May Point to Solution for Global Pandemic

Swift Biosciences, Inc., a leader in commercialization of DNA and RNA library preparation kits for Next-Generation Sequencing (NGS), has announced the release of its Swift Normalase™ Amplicon Panel (SNAP) SARS-CoV-2 kit. Targeting the full viral genome in a single tube reaction with a rapid 2-hour workflow, Swift’s assay enables resea